Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shandong Chia Tai Freda Pharmaceutical Co. Ltd.

Division of Valeant Pharmaceuticals International Inc.
www.cp-freda.com

Latest From Shandong Chia Tai Freda Pharmaceutical Co. Ltd.

Shire Names First China Country President As Multinational Firms Explore New Growth Models

After an eventful summer for the pharma industry in China, multinational companies are exploring new ways to drive growth in the fast-changing market. One of the emerging themes is a consolidated and focused approach, underscored by recent personnel changes at Shire and Johnson & Johnson.

BioPharmaceutical China

Shire And Mylan Start New Era In Japan: Emerging Markets Roundup (Part 6)

Shire’s ADHD portfolio was a boost in Japan, but also carries high risk of generic cannibalization in the near future. Mylan and Pfizer ready to launch first generic tacrolimus in Japan next month.

BioPharmaceutical Japan

A New CEO And Perhaps A New Era At Shire: An Interview With Flemming Ornskov

Making his public debut as Shire CEO at the World Orphan Drug Congress, Flemming Ornskov spoke about his four-month transition period as Angus Russell’s designated successor, how his background in pediatrics may guide business development, and whether he plans to revise the specialty pharma’s business model or hew to his predecessor’s course.

BioPharmaceutical Europe

A New CEO And Perhaps A New Era At Shire: An Interview With Flemming Ornskov

Making his public debut as Shire CEO at the World Orphan Drug Congress, Flemming Ornskov talked with “The Pink Sheet” about his four-month transition period as Angus Russell’s designated successor, how his background in pediatrics may guide business development, and whether he plans to revise the specialty pharma’s business model or hew to his predecessor’s course.

BioPharmaceutical Europe
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register